An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) ...

In a Johns Hopkins Children’s Center study, the addition of navitoclax to the standard TB treatment significantly increased ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients show molecular alterations in the ALK gene involved in cell multiplication.

John Seymour, MBBS, FRACP, PhD, explains why BCL-2 was considered an undruggable target for so long and what led to the development of effective BCL-2 inhibitors.

Figure 2: Inhibition of caspase 3, apoptosis (caspase ... distinct cellular stress pathways and signal that a stress has occurred through interactions with other BCL-2 family members.

School of Chemistry and Chemical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250353, China ...

Idiopathic pulmonary fibrosis (IPF) is a devastating progressive fibrotic lung disease with a median survival of 2.9 years from diagnosis ... phenotype by multiple pathways that reinforce each ...

Department of Oral and Maxillofacial Surgery, The Affiliated Stomatological Hospital, Nanjing Medical University; State Key Laboratory Cultivation Base of Research, Prevention and Treatment for Oral ...